Wasatch Advisors LP increased its position in shares of biote Corp. (NASDAQ:BTMD - Free Report) by 8.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,392,809 shares of the company's stock after purchasing an additional 107,792 shares during the quarter. Wasatch Advisors LP owned 2.57% of biote worth $7,772,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the company. WINTON GROUP Ltd boosted its position in shares of biote by 7.0% during the 2nd quarter. WINTON GROUP Ltd now owns 47,725 shares of the company's stock worth $357,000 after acquiring an additional 3,124 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of biote in the 2nd quarter valued at $42,000. MetLife Investment Management LLC increased its stake in shares of biote by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 16,582 shares of the company's stock valued at $93,000 after purchasing an additional 9,343 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of biote during the 2nd quarter worth $84,000. Finally, Rhumbline Advisers lifted its position in shares of biote by 104.2% during the 2nd quarter. Rhumbline Advisers now owns 28,225 shares of the company's stock worth $211,000 after buying an additional 14,404 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.
biote Trading Down 1.0 %
biote stock traded down $0.07 during midday trading on Friday, reaching $6.61. The company's stock had a trading volume of 41,680 shares, compared to its average volume of 197,092. The stock has a market cap of $359.19 million, a PE ratio of 25.42 and a beta of 0.94. biote Corp. has a 52 week low of $3.65 and a 52 week high of $8.44. The business has a 50-day moving average price of $5.59 and a 200-day moving average price of $6.31.
biote Company Profile
(
Free Report)
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
Featured Articles
Before you consider biote, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.
While biote currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
